Stockreport

Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story [Yahoo! Finance]

Valneva SE - American Depositary Shares  (VALN) 
PDF Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did not meet its primary endpoint, mainly due [Read more]